{"id":"W4392928363","doi":"10.25251/skin.8.supp.396","title":"Bimekizumab Response Maintenance to 48 Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; UCB Pharma; Bausch Health; Swedish Orphan Biovitrum; National and Kapodistrian University of Athens; Insmed; Eisai; Celltrion; XBiotech; Celgene; Amgen; Pfizer; Eli Lilly and Company; Galderma; Incyte","keywords":"Hidradenitis suppurativa; Medicine; Placebo; Double blind; Randomized controlled trial; Clinical trial; Single blind; Internal medicine; Pooled analysis; Meta-analysis; Alternative medicine; Disease; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006430838,0.001453773,0.005844774,0.0006490177,0.0003953399,0.001530771,0.0007579878,0.00194244,0.004649557],"category_scores_gemma":[0.00501173,0.0008125327,0.007720861,0.0006016716,0.0008347724,0.001277048,0.0005043254,0.002689258,0.0006298741],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006226748,"about_ca_system_score_gemma":0.000757791,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007802983,"about_ca_topic_score_gemma":0.001718672,"domain_scores_codex":[0.9968706,0.00213156,0.0002934078,0.0003266437,0.0001605599,0.0002172607],"domain_scores_gemma":[0.9975277,0.001123873,0.0007252846,0.0002184234,0.0001308285,0.0002740422],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9576045,0.0007573843,0.001143432,0.004182656,0.01311997,0.00004163261,0.00004720234,0.0003353811,0.001575176,0.00007250981,0.001202375,0.01991762],"study_design_scores_gemma":[0.9607825,0.02156668,0.006251098,0.0002857093,0.009364878,0.00004734982,0.00004219219,0.0003064427,0.0002918854,0.0001755269,0.0008572069,0.00002859046],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8068239,0.1706932,0.00355674,0.00246171,0.002674202,0.005035346,0.003507185,0.0004150839,0.00483264],"genre_scores_gemma":[0.971751,0.01682573,0.001866614,0.002534093,0.001123335,0.002306194,0.001335624,0.00005183862,0.002205649],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006430838,"threshold_uncertainty_score":0.03400993,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04110841053141875,"score_gpt":0.3781181349803364,"score_spread":0.3370097244489176,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}